These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10858340)

  • 1. Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin.
    Bachoual R; Dubreuil L; Soussy CJ; Tankovic J
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1842-5. PubMed ID: 10858340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
    Oh H; El Amin N; Davies T; Appelbaum PC; Edlund C
    Antimicrob Agents Chemother; 2001 Jul; 45(7):1977-81. PubMed ID: 11408211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
    Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
    Kocagöz T; Hackbarth CJ; Unsal I; Rosenberg EY; Nikaido H; Chambers HF
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1768-74. PubMed ID: 8843279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Pankuch GA; Dewasse BE; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2740-6. PubMed ID: 10991854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
    Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
    J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants.
    Ricci V; Peterson ML; Rotschafer JC; Wexler H; Piddock LJ
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1344-6. PubMed ID: 15047539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin.
    Dubin DT; Fitzgibbon JE; Nahvi MD; John JF
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1631-7. PubMed ID: 10390214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.
    Bébéar CM; Grau O; Charron A; Renaudin H; Gruson D; Bébéar C
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2719-27. PubMed ID: 10991851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
    Heaton VJ; Ambler JE; Fisher LM
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.
    Peterson ML; Hovde LB; Wright DH; Hoang AD; Raddatz JK; Boysen PJ; Rotschafer JC
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2251-5. PubMed ID: 10471574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
    Shultz TR; Tapsall JW; White PA
    Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field.
    Giraud E; Brisabois A; Martel JL; Chaslus-Dancla E
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2131-7. PubMed ID: 10471553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase.
    Onodera Y; Sato K
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2423-9. PubMed ID: 10508019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single or double mutational alterations of gyrA associated with fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli.
    Bachoual R; Ouabdesselam S; Mory F; Lascols C; Soussy CJ; Tankovic J
    Microb Drug Resist; 2001; 7(3):257-61. PubMed ID: 11759087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmid-mediated complementation of gyrA and gyrB in fluoroquinolone-resistant Bacteroides fragilis.
    Peterson ML; Rotschafer JC; Piddock LJ
    J Antimicrob Chemother; 2003 Sep; 52(3):481-4. PubMed ID: 12917248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
    Pestova E; Beyer R; Cianciotto NP; Noskin GA; Peterson LR
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2000-4. PubMed ID: 10428926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.